U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H10NO6P
Molecular Weight 247.1422
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PYRIDOXAL PHOSPHATE ANHYDROUS

SMILES

Cc1c(c(C=O)c(cn1)COP(=O)(O)O)O

InChI

InChIKey=NGVDGCNFYWLIFO-UHFFFAOYSA-N
InChI=1S/C8H10NO6P/c1-5-8(11)7(3-10)6(2-9-5)4-15-16(12,13)14/h2-3,11H,4H2,1H3,(H2,12,13,14)

HIDE SMILES / InChI

Molecular Formula C8H10NO6P
Molecular Weight 247.1422
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20532028 | https://clinicaltrials.gov/ct2/show/NCT00157729 | https://clinicaltrials.gov/ct2/show/NCT00917293 | https://www.ncbi.nlm.nih.gov/pubmed/12213051 | https://www.ncbi.nlm.nih.gov/pubmed/23510563

Pyridoxal phosphate (PLP, pyridoxal 5'-phosphate, P5P) is a coenzyme, the active form of vitamin B6. Pyridoxal 5′-phosphate (PLP) is used as a cofactor for a wide range of enzymes including mitochondrial cysteine desulfurase, cystathionine γ-synthase (CGS), ornithine 4,5-aminomutase (OAM), and d-serine dehydratase. The versatility of PLP arises from its ability to covalently bind the substrate, and then to act as an electrophilic catalyst, thereby stabilizing different types of carbanionic reaction intermediates. PLP acts as a coenzyme in all transamination reactions, in various beta-elimination reactions, in the condensation reaction in heme synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3000.0 nM [EC50]
39500.0 nM [EC50]
10.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats.
2001
The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: possible involvement of vanilloid receptors.
2001 Apr
Renal microvascular effects of P2 receptor stimulation.
2001 Apr
Crystal structure of maltose phosphorylase from Lactobacillus brevis: unexpected evolutionary relationship with glucoamylases.
2001 Aug
A bioinformatical approach suggests the function of the autoimmune hepatitis target antigen soluble liver antigen/liver pancreas.
2001 Aug
Do ATP and UTP involve cGMP in positive inotropism on rat atria?
2001 Feb
Analysis of purine- and pyrimidine-induced vascular responses in the isolated rat cerebral arteriole.
2001 Feb
Brain succinic semialdehyde dehydrogenase: identification of reactive lysyl residues labeled with pyridoxal-5'-phosphate.
2001 Feb
Inhibitors of advanced glycation end product-associated protein cross-linking.
2001 Feb 14
Occurrence of D-Amino Acids and a pyridoxal 5'-phosphate-dependent aspartate racemase in the acidothermophilic archaeon, Thermoplasma acidophilum.
2001 Feb 23
Clinical adaptation of a high-performance liquid chromatographic method for the assay of pyridoxal 5'-phosphate in human plasma.
2001 Feb 25
Identification and characterization of an aromatic amino acid decarboxylase from the filarial nematode, Dirofilaria immitis.
2001 Jan
Characterization of prejunctional purinoceptors inhibiting noradrenaline release in rat mesenteric arteries.
2001 Jan
Phylogenetic analyses and comparative genomics of vitamin B6 (pyridoxine) and pyridoxal phosphate biosynthesis pathways.
2001 Jan
Pyridoxal 5'-phosphate-dependent alpha,beta-elimination reactions: mechanism of O-acetylserine sulfhydrylase.
2001 Jan
The value of MnDPDP enhancement during MR guided laser interstitial thermoablation of liver tumors.
2001 Jan
Multiple P2X receptors on guinea-pig pelvic ganglion neurons exhibit novel pharmacological properties.
2001 Jan
Site-directed mutagenesis of K396R of the 65 kDa glutamic acid decarboxylase active site obliterates enzyme activity but not antibody binding.
2001 Jan 19
Detection of bile duct leaks using MR cholangiography with mangfodipir trisodium (Teslascan).
2001 Jan-Feb
Cassette mutagenesis of lysine 130 of human glutamate dehydrogenase. An essential residue in catalysis.
2001 Jun
PPADS, an ATP antagonist, attenuates the effects of a moderately intense sound on cochlear mechanics.
2001 Jun
Pyridoxal phosphate binding sites are similar in human heme-dependent and yeast heme-independent cystathionine beta-synthases. Evidence from 31P NMR and pulsed EPR spectroscopy that heme and PLP cofactors are not proximal in the human enzyme.
2001 Jun 1
Three-dimensional structure of 2-amino-3-ketobutyrate CoA ligase from Escherichia coli complexed with a PLP-substrate intermediate: inferred reaction mechanism.
2001 May 1
Crystal structures of 1-aminocyclopropane-1-carboxylate (ACC) synthase in complex with aminoethoxyvinylglycine and pyridoxal-5'-phosphate provide new insight into catalytic mechanisms.
2001 Oct 12
P2Y(AC)(-)-receptor agonists enhance the proliferation of rat C6 glioma cells through activation of the p42/44 mitogen-activated protein kinase.
2001 Sep
Cloning and characterization of a functional P2X receptor from larval bullfrog skin.
2001 Sep
Patents

Sample Use Guides

500 mgs po bid for 12 weeks.
Route of Administration: Oral
Male Wistar rat (body weight -200 g) was sacrificed by bleeding from the right femoral artery under diethyl ether anesthesia. A thoracic aorta was removed and washed with RPMI 1640 medium to avoid contamination with blood. It was then turned inside out, and cut into short segments of about 1-1.5 mm. Each aortic segment was placed in the center of a well on a 6-well culture plate and covered with 0.5 ml of gel matrix solution reconstituted as described. The solution was allowed to gel at 37°C for 20 min, and then overlaid with 2 ml of RPMI 1640 medium (Gibco, New York, USA) containing 1% of ITS+ (Becton Dickinson Labware, MA, USA). PLP (Pyridoxal phosphate ) was reconstituted in phosphate buffered saline and added on day 1. Incubation was carried out for 10 days in a fully humidified system of 5% C02 in the air at 37°C. The medium was changed on day 7 of the culture.
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:27:01 UTC 2021
Edited
by admin
on Sat Jun 26 07:27:01 UTC 2021
Record UNII
F06SGE49M6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PYRIDOXAL PHOSPHATE ANHYDROUS
Common Name English
NSC-82388
Code English
PYRIDOXAL 5-MONOPHOSPHORIC ACID ESTER
Common Name English
3-HYDROXY-5-(HYDROXYMETHYL)-2-METHYLISONICOTINALDEHYDE 5-PHOSPHATE
Common Name English
PYRIDOXAL PHOSPHATE [WHO-DD]
Common Name English
VITAMIN B6 (PYRIDOXAL 5-PHOSPHATE)
Common Name English
PYRIDOXAL 5-PHOSPHATE [MI]
Common Name English
PYRIDOXAL 5-PHOSPHATE
INCI   MI  
INCI  
Official Name English
PYRIDOXAL 5-PHOSPHATE [INCI]
Common Name English
3-HYDROXY-2-METHYL-5-((PHOSPHONOOXY)METHYL)-4-PYRIDINECARBOXALDEHYDE
Systematic Name English
PYRIDOXAL 5'-PHOSPHATE [VANDF]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/18/1983
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
WHO-ATC C10AX07
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
DSLD 2529 (Number of products:1084)
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
Code System Code Type Description
MERCK INDEX
M9362
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB05315
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY
RXCUI
1599827
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY RxNorm
PUBCHEM
1051
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY
EPA CompTox
54-47-7
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY
EVMPD
SUB04137MIG
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY
FDA UNII
F06SGE49M6
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-208-3
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY
CAS
54-47-7
Created by admin on Sat Jun 26 07:27:01 UTC 2021 , Edited by admin on Sat Jun 26 07:27:01 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY